Latest Breaking News On - Claire duvernoy - Page 1 : comparemela.com

May 17, 2021 A de-escalation antiplatelet strategy of switching from the more-potent ticagrelor (Brilinta; AstraZeneca) to clopidogrel at 1 month after PCI for acute MI is superior to continuing on ticagrelor and aspirin in terms of net clinical benefit, according to the TALOS-AMI trial. “This study was conducted only in South Korea. However, although the prevalence of the CYP2C19 loss-of-function allele is significantly higher in Koreans than in other ethnic groups, this study showed the clinical safety of switching in this population, suggesting the potential of applying this de-escalation strategy to other ethnic groups,” said Kiyuk Chang, MD, PhD (The Catholic University of Korea, Seoul, Republic of Korea), who presented the findings in a late-breaking clinical trial session yesterday at the American College of Cardiology 2021 Scientific Session.

New yorkUnited statesSoult ukpyolsiSouth koreaAnn arborRepublic of koreaClaire duvernoyRoxana mehranKiyuk changMd university of michigan health systemAmerican college of cardiologyCatholic university of koreaCatholic universityAmerican collegeMichigan health systemIcahn school